Peptide Comparison
Tesamorelin vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two GHRHs in the same regimen: Moderate risk per peptide research literature. Same receptor: competition at pituitary GHRH receptor; no additive benefit, reduced efficiency.
Data-derived verdict
Tesamorelin has stronger documented evidence (FDA-Approved) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Tesamorelin | Sermorelin | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | SC injection | SC injection |
| Half-life | ~26 min | ~10-20 min |
| Dosage (research) | 2 mg SC daily (FDA label) | 200-500 mcg SC at bedtime daily |
| Evidence tier | FDA-Approved | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 165 indexed | 247 indexed |
| Availability | Prescription | Compounding Restricted |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or Sermorelin?
Tesamorelin has stronger documented evidence (FDA-Approved) than Sermorelin (Discontinued (FDA approval 1990; US withdrawal 2008)) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. Sermorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Tesamorelin and Sermorelin?
Tesamorelin is classed as GHRH analog (FDA-approved); Sermorelin is classed as GHRH analog. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: Tesamorelin, ~26 min; Sermorelin, ~10-20 min. Routes in published studies: Tesamorelin, SC injection; Sermorelin, SC injection.
Which has stronger evidence, Tesamorelin or Sermorelin?
Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 10 cited sources on its reference page and 165 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 247 indexed studies.
Which is more accessible, Tesamorelin or Sermorelin?
Tesamorelin is FDA-approved and Sermorelin is not. Catalog status: Tesamorelin, Prescription; Sermorelin, Compounding Restricted.
Are Tesamorelin and Sermorelin ever combined?
Tesamorelin and Sermorelin appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two GHRHs in the same regimen, moderate risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…